The Pharmaceutical Partnering Yearbook 2013 report series provides
comprehensive understanding and unprecedented access to the partnering deals and
agreements entered into by the worlds leading healthcare companies during 2012.
Using these reports, dealmakers will effectively and efficiently gain insight
into the partnering activities of the past year. The report series allows you to
view all the partnering and alliances deals announced worldwide.
The initial chapters of this report provide an orientation of 2012s dealmaking
and business activities.
Chapter 1 provides an overview of the trends in dealmaking during 2012 covering
trends by deal type, stage of development, technology type and therapeutic
indication.
Chapter 2 provides a review of the leading deals during 2012. Deals are listed
by headline value, signed by bigpharma and bigbiotech, and most active bigpharma.
Where the deal has an agreement contract published at the SEC a link provides
online access to the contract.
Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of 2012 deals, as well
as contract documents available in the public domain. Each deal title links via
Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
Chapter 4 provides a comprehensive directory of all partnering deals announced
during 2012.
The chapter is organized by company A-Z, stage of development at signing, deal
type (collaborative R&D, co-promotion, licensing etc), therapy area and
technology type. Each deal title links via Weblink to an online version of the
deal record and where available, the contract document, providing easy access to
each contract document on demand.
The report series also includes numerous tables and figures that illustrate the
trends and activities in bigpharma partnering and dealmaking during 2012.
In conclusion, this report provides everything a prospective dealmaker needs to
know about partnering in the research, development and commercialization of
technologies and products during 2012.
Key benefits
Pharmaceutical Partnering Yearbook 2013 series provides the reader with the
following key benefits:
- In-depth understanding of recent dealmaking trends during 2012
- Comprehensive access to all deals entered into by the worlds biopharma
companies during 2012
- Detailed access to actual partnership deals and contracts entered into by
the leading fifty bigpharma companies
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
Report scope
Pharmaceutical Partnering Yearbook 2013 series is intended to provide the reader
with an in-depth understanding and access to parthering and M&A trends and
structure of deals entered into by leading companies worldwide.
Pharmaceutical Partnering Yearbook 2013 includes:
- Trends in dealmaking in the biopharma industry during 2012
- Comprehensive directory of partnering deals in 2012
- Links to online access to all deals and alliances
- The leading partnering deals by value in 2012
- Most active partnering dealmakers during 2012
In Pharmaceutical Partnering Yearbook 2012 series the partnering and M&A
deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Therapy area
- Technology type
Each deal title links via Weblink to an online version of the deal record at
Current Agreements and where available, the contract document, providing easy
access to each contract document on demand.
Executive Summary
Chapter 1 Trends in dealmaking during 2012
1.1. Bigpharma dealmaking activity
1.2. Partnering by deal type
1.3. Partnering by industry sector
1.4. Partnering by stage of development
1.5. Partnering by technology type
1.6. Partnering by therapy area
Chapter 2 Leading deals during 2012
2.1. Introduction
2.2. Top deals by value during 2012
Chapter 3 Bigpharma deals during 2012
3.1. Introduction
3.2. How to use bigpharma partnering deals
3.3. Bigpharma partnering company profiles for 2012
Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson
Chapter 4 Partnering deals directory 2012
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By stage of development
4.5. By technology type
4.6. By therapy area
About Wildwood Ventures
Current Partnering
Current Agreements
Current Reports
Recent titles from CurrentPartnering
Order Form Reports
Table of Figures
Figure 1: Bigpharma top 50 January to December 2012
Figure 2: Bigpharma deal frequency 2012
Figure 3: Partnering by deal type during 2012
Figure 4: Partnering by industry sector during 2012
Figure 5: Partnering by stage of development during 2012
Figure 6: Partnering by technology type during 2012
Figure 7: Partnering by therapy area during 2012
Figure 8: Top deals by value during 2012
0 items in cart
